Combination of hsa_circ_0004674 and lncRNA OIP5‑AS1 as a novel clinical biomarker used to predict prognosis in patients with osteosarcoma

Zhu,Yu-Run; Zhu,Kun-Peng; Hu,Jian-Ping; Tan,Shuo; Zhang,Chun-Lin

doi:10.3892/etm.2023.11907

Combination of hsa_circ_0004674 and lncRNA OIP5‑AS1 as a novel clinical biomarker used to predict prognosis in patients with osteosarcoma

Authors:
- Yu-Run Zhu
- Kun-Peng Zhu
- Jian-Ping Hu
- Shuo Tan
- Chun-Lin Zhang
View Affiliations

Affiliations: Department of Orthopedics, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, P.R. China
Published online on: March 23, 2023 https://doi.org/10.3892/etm.2023.11907
Article Number: 208
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma is a malignant tumor that predominantly occurs in children or adolescents under the age of 20 years old. Metastasis and chemotherapy resistance are two problems in the treatment of osteosarcoma, and the lack of definite biomarkers impairs the course of treatment. In recent years, non‑coding RNA, as a biomarker of osteosarcoma, has become an area of research focus. The role of long non‑coding RNAs (lncRNAs), such as lncRNA OIP5‑AS1, and circular RNAs, such as hsa_circ_0004674, in osteosarcoma have previously been revealed, and the present study investigated their clinical significance. A total of 20 samples were collected from patients with osteosarcoma. The expression levels of lncRNA OIP5‑AS1 and hsa_circ_0004674 were analyzed in tumor tissues and patient serum, and their associations with chemotherapy sensitivity, lung metastasis and prognosis were assessed. The results revealed that these two non‑coding RNAs were significantly upregulated in the osteosarcoma tissues of patients compared with those in the adjacent tumor tissues. In addition, the expression levels of the two non‑coding RNAs were increased in the serum of patients with osteosarcoma compared with those in patients with bone fractures (P<0.01). In patients with lung metastasis or chemotherapy resistance (tumor necrosis rate <90%), the expression levels of the two non‑coding RNAs were similarly increased. By plotting the receiver operating characteristic curve, it was revealed that the combination of hsa_circ_0004674 and lncRNA OIP5‑AS1 was better than ALP or either non‑coding RNA alone in predicting chemotherapy sensitivity and metastasis. Kaplan‑Meier survival analysis showed that, in patients with osteosarcoma, higher expression of both non‑coding RNAs was associated with worse survival time (log‑rank test P=0.006). In conclusion, the combination of hsa_circ_0004674 and lncRNA OIP5‑AS1 may be used as a better biomarker than traditional biomarkers, such as ALP, in a clinical setting.

View Figures

View References

1	Liao D, Zhong L, Yin J, Zeng C, Wang X, Huang X, Chen J, Zhang H, Zhang R, Guan XY, et al: Chromosomal translocation-derived aberrant Rab22a drives metastasis of osteosarcoma. Nat Cell Biol. 22:868–881. 2020.PubMed/NCBI View Article : Google Scholar
2	Fang Y and Fullwood MJ: Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteomics Bioinformatics. 14:42–54. 2016.PubMed/NCBI View Article : Google Scholar
3	Chen H, Xu Z and Liu D: Small non-coding RNA and colorectal cancer. J Cell Mol Med. 23:3050–3057. 2019.PubMed/NCBI View Article : Google Scholar
4	Zhao W, Zhang D, Qin P, Zhang J, Cui X, Gao J, Wang J and Li J: Long non-coding RNA EPIC1 inhibits viability and invasion of osteosarcoma cells by promoting MEF2D ubiquitylation. Int J Biol Macromol. 128:566–573. 2019.PubMed/NCBI View Article : Google Scholar
5	Wang J, Cao L, Wu J and Wang Q: Long non-coding RNA SNHG1 regulates NOB1 expression by sponging miR-326 and promotes tumorigenesis in osteosarcoma. Int J Oncol. 52:77–88. 2018.PubMed/NCBI View Article : Google Scholar
6	Chen B and Huang S: Circular RNA: An emerging non-coding RNA as a regulator and biomarker in cancer. Cancer Lett. 418:41–50. 2018.PubMed/NCBI View Article : Google Scholar
7	Jin J, Chen A, Qiu W, Chen Y, Li Q, Zhou X and Jin D: Dysregulated circRNA_100876 suppresses proliferation of osteosarcoma cancer cells by targeting microRNA-136. J Cell Biochem. 120:15678–15687. 2019.PubMed/NCBI View Article : Google Scholar
8	Wu Y, Xie Z, Chen J, Chen J, Ni W, Ma Y, Huang K, Wang G, Wang J, Ma J, et al: Circular RNA circTADA2A promotes osteosarcoma progression and metastasis by sponging miR-203a-3p and regulating CREB3 expression. Mol Cancer. 18(73)2019.PubMed/NCBI View Article : Google Scholar
9	Kun-Peng Z, Chun-Lin Z, Xiao-Long M and Lei Z: Fibronectin-1 modulated by the long noncoding RNA OIP5-AS1/miR-200b-3p axis contributes to doxorubicin resistance of osteosarcoma cells. J Cell Physiol. 234:6927–6939. 2019.PubMed/NCBI View Article : Google Scholar
10	Kun-Peng Z, Chun-Lin Z, Jian-Ping H and Lei Z: A novel circulating hsa_circ_0081001 act as a potential biomarker for diagnosis and prognosis of osteosarcoma. Int J Biol Sci. 14:1513–1520. 2018.PubMed/NCBI View Article : Google Scholar
11	Zhu KP, Ma XL and Zhang CL: LncRNA ODRUL contributes to osteosarcoma progression through the miR-3182/MMP2 axis. Mol Ther. 25:2383–2393. 2017.PubMed/NCBI View Article : Google Scholar
12	Ma XL, Zhan TC, Hu JP, Zhang CL and Zhu KP: Doxorubicin-induced novel circRNA_0004674 facilitates osteosarcoma progression and chemoresistance by upregulating MCL1 through miR-142-5p. Cell Death Discov. 7(309)2021.PubMed/NCBI View Article : Google Scholar
13	Dai J, Xu L, Hu X, Han G, Jiang H, Sun H, Zhu G and Tang X: Long noncoding RNA OIP5-AS1 accelerates CDK14 expression to promote osteosarcoma tumorigenesis via targeting miR-223. Biomed Pharmacother. 106:1441–1447. 2018.PubMed/NCBI View Article : Google Scholar
14	Song L, Zhou Z, Gan Y, Li P, Xu Y, Zhang Z, Luo F, Xu J, Zhou Q and Dai F: Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p. J Cell Biochem. 120:9656–9666. 2019.PubMed/NCBI View Article : Google Scholar
15	Almeida E, Mascarenhas BA, Cerqueira A and Medrado AR: Chondroblastic osteosarcoma. Oral Maxillofac Pathol. 18:464–468. 2014.PubMed/NCBI View Article : Google Scholar
16	Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, et al: Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A joint study by the Italian and Scandinavian sarcoma groups. J Clin Oncol. 23:8845–8852. 2005.PubMed/NCBI View Article : Google Scholar
17	Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A and Picci P: Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-Year experience in 789 patients treated at a single institution. Cancer. 106:1154–1161. 2006.PubMed/NCBI View Article : Google Scholar
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
19	Miwa S, Shirai T, Yamamoto N, Hayashi K, Takeuchi A, Igarashi K and Tsuchiya H: Current and emerging targets in immunotherapy for osteosarcoma. J Oncol. 2019(7035045)2019.PubMed/NCBI View Article : Google Scholar
20	Bacci G, Mercuri M, Briccoli A, Ferrari S, Bertoni F, Donati D, Monti C, Zanoni A, Forni C and Manfrini M: Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. Cancer. 79:245–254. 1997.PubMed/NCBI
21	Brooks JD: Translational genomics: The challenge of developing cancer biomarkers. Genome Res. 22:183–187. 2012.PubMed/NCBI View Article : Google Scholar
22	Xiao H, Zhang F, Zou Y, Li J, Liu Y and Huang W: The function and mechanism of long non-coding RNA-ATB in cancers. Front Physiol. 9(321)2018.PubMed/NCBI View Article : Google Scholar
23	Smolle MA, Prinz F, Calin GA and Pichler M: Current concepts of non-coding RNA regulation of immune checkpoints in cancer. Mol Aspects Med. 70:117–126. 2019.PubMed/NCBI View Article : Google Scholar
24	Wang Y, Zeng X, Wang N, Zhao W, Zhang X, Teng S, Zhang Y and Lu Z: Long noncoding RNA DANCR, working as a competitive endogenous RNA, promotes ROCK1-mediated proliferation and metastasis via decoying of miR-335-5p and miR-1972 in osteosarcoma. Mol Cancer. 17(89)2018.PubMed/NCBI View Article : Google Scholar
25	Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, Huang D, Chen X, Zhang H, Zhuang R, et al: A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer. 47:784–791. 2011.PubMed/NCBI View Article : Google Scholar
26	Ren HY, Sun LL, Li HY and Ye ZM: Prognostic significance of serum alkaline phosphatase level in osteosarcoma: A meta-analysis of published data. Biomed Res Int. 2015(160835)2015.PubMed/NCBI View Article : Google Scholar
27	Marais LC, Bertie J, Rodseth R, Sartorius B and Ferreira N: Pre-treatment serum lactate dehydrogenase and alkaline phosphatase as predictors of metastases in extremity osteosarcoma. J Bone Oncol. 4:80–84. 2015.PubMed/NCBI View Article : Google Scholar
28	Yotsukura S and Mamitsuka H: Evaluation of serum-based cancer biomarkers: A brief review from a clinical and computational viewpoint. Crit Rev Oncol Hematol. 93:103–115. 2015.PubMed/NCBI View Article : Google Scholar